ArticleBMC ophthalmology2025
Associations between serum neuropeptide Y levels and anxiety, depression, and quality of life in Chinese patients with primary glaucoma.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Research progress on glaucoma complicated with anxiety and depression.International journal of ophthalmology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundPatients with glaucoma demonstrate significantly elevated prevalence rates of anxiety and depression compared to healthy controls, although these psychiatric comorbidities remain frequently underrecognised in clinical practice. This study evaluated serum neuropeptide Y (NPY) concentrations in patients with primary glaucoma to investigate potential associations with anxiety, depression, and quality of life (QOL).
methodsThe study cohort comprised 45 healthy controls and 89 patients with primary glaucoma, including 55 patients with primary open-angle glaucoma (POAG) and 34 patients with primary angle-closure glaucoma (PACG). Peripheral blood samples were collected, and anxiety, depression, and QOL scores were recorded. Serum NPY levels were measured using an enzyme-linked immunosorbent assay. Univariate analyses and multivariate logistic regression analyses were employed.
resultsSerum NPY concentrations were significantly lower in primary glaucoma patients than in healthy individuals (P < 0.001). Among glaucoma patients, those with comorbid anxiety or depressive disorders presented markedly lower NPY levels than patients without anxiety and depression (P < 0.001). Multivariate analysis revealed that in the glaucoma cohort, anxiety was significantly associated with serum NPY levels, economic burden, and increased intraocular pressure in both eyes, whereas depression was significantly associated with serum NPY levels and economic burden. The QOL scores revealed that serum NPY levels were positively correlated with bodily pain and role-physical in primary glaucoma patients with comorbid anxiety. Similarly, NPY levels were positively correlated with mental health in primary glaucoma patients with depression. Furthermore, serum NPY levels in primary glaucoma patients were associated with MD values in the worse eye.
conclusionSerum NPY concentrations were identified as an independent predictor of both anxiety and depression in patients with primary glaucoma. Moreover, lower serum NPY levels were significantly inversely associated with glaucoma severity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.